The clinical trial for mexiletine in sporadic amyotrophic lateral sclerosis (SALS) aims to explore its potential to reduce cortical hyperexcitability and slow disease progression. Given the lack of effective treatments for ALS, a successful outcome could position mexiletine as a novel therapeutic option in a market with significant unmet needs. The competitive landscape includes existing therapies like riluzole and edaravone, but mexiletine's unique mechanism may provide a differentiated profile. Diligence should focus on the safety profile, potential market entry barriers, and the regulatory pathway, especially considering mexiletine's prior FDA approval for other indications.